Product Images Tymlos

This is a description of a study on patient nonvertebral fracture incidence for alendronate monotherapy. The graph shows the incidence of fractures over a period of 25 months, with alendronate treatment starting at 19 months. The study compared the efficacy of alendronate to placebo and TYMLOS over a period of 25 months.*

This is a description of the TYMLOS pen, including the cartridge, cartridge holder, pen cap, injection button, dose knob, dose display window, and lot/exp information. There are two views of the pen provided: a front view and a rear view.*

This text is a list of items that are not included with the TYMLOS pen but are necessary parts of the pen needle, including the inner and outer pen needle caps, and the protective paper for the pen needle. The figure C likely refers to an accompanying diagram or illustration.*

TYMLOS' is a medication that is given through subcutaneous injection using a pre-filled pen. It contains 3120 mcg/1.56 mL (2000 mg/m) of ahaloparatide. The medication should be kept refrigerated until the first use, after which it can be stored at room temperature for up to 30 days. Unused portions should be discarded after 30 days. Before injecting, read the instructions for use carefully.*

TYMLOS' (abaloparatide) injection is a prescription drug for subcutaneous use and is meant for single patient use only. Each pre-filled pen contains enough doses for 30 injections. The medication needs to be kept refrigerated at 2°C - 8°C (36°F - 46°F) before the first use and after that, it can be stored for up to 30 days at a temperature range of 20°C - 25°C (68°F - 77°F). Unused portions should be discarded 30 days after opening. Before injecting, it is important to read the instructions for use. The drug is manufactured by Radius Health, Inc. in Boston, MA.*